EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Clinical trials for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC) explained in plain language.
Never miss a new study
Get alerted when new EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC) trials appear
Sign up with your email to follow new studies for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a Triple-Drug combo outsmart a rare and aggressive cancer?
Disease control Not yet recruitingThis clinical trial is testing whether adding two newer drugs—QL1706 and lenvatinib—to standard chemotherapy can help people with a rare and aggressive cancer called extrapulmonary neuroendocrine carcinoma (EP-NEC). The study will compare the combination against chemotherapy alon…
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Engineered immune cells take on tough cancers in first human trial
Disease control Not yet recruitingThis early-phase trial tests a new treatment called ML261 for people with advanced small cell lung cancer or certain neuroendocrine cancers that have not responded to standard treatments. ML261 is made from a patient's own immune cells, which are modified in a lab to better recog…
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Phase: PHASE1 • Sponsor: Moonlight Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC